ExThera Medical Wins a Gold Edison Award for COVID-19 Innovations: Therapeutic Impact for the Seraph® 100 Blood Filter
May 10, 2022

MARTINEZ, Calif. – ExThera Medical has been announced as the 2022 Gold winner of the Edison Award in the “COVID-19 Innovations Therapeutic Impact” category for the development of the Seraph 100, a groundbreaking device used in the treatment of critically ill COVID-19 patients.

The Edison Awards is an annual honor recognizing excellence in new product and service development, marketing, human-centered design, and innovation. Started in 1987 and named after Thomas Edison, the vision of the Edison Awards is guided by his legacy and vision and his Menlo Park team who successfully brought an unprecedented number of innovations to the market. Edison Award recipients represent “game changing” products, services, excellence, and leadership in innovation around four criteria: Concept, Value, Delivery and Impact.

“It is an incredible honor to be recognized by such a highly regarded organization such as the Edison Awards,” said ExThera Medical CEO Robert Ward. “Thomas Edison was a boyhood hero of mine and I’ve visited his laboratories in West Orange, NJ and Fort Myers, FL. We are proud to be saving lives during the COVID-19 pandemic under our FDA Emergency Use Authorization with Seraph 100 and very happy to have been recognized as an Edison Award winner.”

The Seraph 100 has been granted Investigational Device Exemption by the Food and Drug Administration to treat COVID-19 patients admitted to the ICU with confirmed or imminent respiratory failure. The Seraph 100 is the first blood purification device to be shown to reduce both bacterial and viral loads in the bloodstream and has been used on more than 1,000 US and EU patients since April 2020. A multicenter randomized controlled trial studying blood purification for the treatment of pathogen associated shock during sepsis (PURIFY-RCT) has been initiated and began enrollment earlier this year.

 

# # #

About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) for removing a broad range of pathogens from the bloodstream of patients. Seraph 100 can be used in hospitals, clinics, on battlefields and in other austere environments to address nosocomial and community-acquired infections as well as those caused by battlefield wounds, pandemics, and biological warfare agents. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis, COVID-19, and many other severe bloodstream infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the U.S., the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. 

The Seraph 100 Microbind Affinity Blood Filter (Seraph 100) attained CE Mark in 2019 and is commercially available in the EU for the treatment of blood stream infections. The Seraph 100 device has neither been cleared nor approved by the U.S. Food and Drug Administration (FDA) for any indication. The Seraph 100 has been authorized by FDA under an Emergency Use Authorization (EUA) to treat patients with COVID-19 infection. The Seraph 100 is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Seraph 100 device under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

For more information, visit the company’s website at https://extheramedical.com/.

About Seraph 100 and the ONCObind Procedure
As a patient’s blood flows through the Seraph® 100 Microbind® Affinity Filter (Seraph 100), it passes through a bed of small beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Many harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph 100 adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s proprietary adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind circulating tumor cells, bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.

ExThera Medical is currently developing the ONCObind Procedure Hemoperfusion Filter (ONCObind) to support cancer treatment. ONCObind is part of the same platform technology as Seraph 100.

For more news stories on Seraph 100 and ONCObind, click here.

Disclaimer
All information contained in this news release derives from plausible, reliable sources, however they have not been independently examined or verified. There is no representation, warranty, or guarantee provided herein. Except as otherwise required by appliable law, all liability for any direct or indirect claims, damages or losses are hereby disclaimed whether or not foreseeable. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Accordingly, the investment and/or the revenues that arise from it can rise or fall or fail entirely. We assume no responsibility to update or revise any statements contained in this news release, including forward-looking, to reflect events, trends, or circumstances that might arise after the date of this news release. Results from case studies (reviews) may not be predictive of future results.

MM0044 Rev A

MM0006 Rev E